182 related articles for article (PubMed ID: 37688579)
21. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.
Mirabello L; Zhu B; Koster R; Karlins E; Dean M; Yeager M; Gianferante M; Spector LG; Morton LM; Karyadi D; Robison LL; Armstrong GT; Bhatia S; Song L; Pankratz N; Pinheiro M; Gastier-Foster JM; Gorlick R; de Toledo SRC; Petrilli AS; Patino-Garcia A; Lecanda F; Gutierrez-Jimeno M; Serra M; Hattinger C; Picci P; Scotlandi K; Flanagan AM; Tirabosco R; Amary MF; Kurucu N; Ilhan IE; Ballinger ML; Thomas DM; Barkauskas DA; Mejia-Baltodano G; Valverde P; Hicks BD; Zhu B; Wang M; Hutchinson AA; Tucker M; Sampson J; Landi MT; Freedman ND; Gapstur S; Carter B; Hoover RN; Chanock SJ; Savage SA
JAMA Oncol; 2020 May; 6(5):724-734. PubMed ID: 32191290
[TBL] [Abstract][Full Text] [Related]
22. [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
Liu WL; Zhao JZ; Wang ZZ; Dong B; Hou YY; Wu XX; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jun; 52(6):403-410. PubMed ID: 28647964
[No Abstract] [Full Text] [Related]
23. Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma.
Egolf LE; Vaksman Z; Lopez G; Rokita JL; Modi A; Basta PV; Hakonarson H; Olshan AF; Diskin SJ
Am J Hum Genet; 2019 Sep; 105(3):658-668. PubMed ID: 31474320
[TBL] [Abstract][Full Text] [Related]
24. Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans.
Latorre V; Diskin SJ; Diamond MA; Zhang H; Hakonarson H; Maris JM; Devoto M
Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):658-63. PubMed ID: 22328350
[TBL] [Abstract][Full Text] [Related]
25. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
[TBL] [Abstract][Full Text] [Related]
26. BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.
Vahteristo P; Syrjäkoski K; Heikkinen T; Eerola H; Aittomäki K; von Smitten K; Holli K; Blomqvist C; Kallioniemi OP; Nevanlinna H
Eur J Hum Genet; 2006 Feb; 14(2):167-72. PubMed ID: 16333312
[TBL] [Abstract][Full Text] [Related]
27. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Spurdle AB; Marquart L; McGuffog L; Healey S; Sinilnikova O; Wan F; Chen X; Beesley J; Singer CF; Dressler AC; Gschwantler-Kaulich D; Blum JL; Tung N; Weitzel J; Lynch H; Garber J; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Conroy D; Evans DG; Lalloo F; Eeles R; Izatt L; Davidson R; Chu C; Eccles D; Selkirk CG; Daly M; Isaacs C; Stoppa-Lyonnet D; Sinilnikova OM; Buecher B; Belotti M; Mazoyer S; Barjhoux L; Verny-Pierre C; Lasset C; Dreyfus H; Pujol P; Collonge-Rame MA; ; Rookus MA; Verhoef S; Kriege M; Hoogerbrugge N; Ausems MG; van Os TA; Wijnen J; Devilee P; Meijers-Heijboer HE; Blok MJ; Heikkinen T; Nevanlinna H; Jakubowska A; Lubinski J; Huzarski T; Byrski T; Durocher F; Couch FJ; Lindor NM; Wang X; Thomassen M; Domchek S; Nathanson K; Caligo M; Jernström H; Liljegren A; Ehrencrona H; Karlsson P; ; Ganz PA; Olopade OI; Tomlinson G; Neuhausen S; Antoniou AC; Chenevix-Trench G; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1032-8. PubMed ID: 21393566
[TBL] [Abstract][Full Text] [Related]
28. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H
J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532
[TBL] [Abstract][Full Text] [Related]
29. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma.
Nassar AH; Abou Alaiwi S; AlDubayan SH; Moore N; Mouw KW; Kwiatkowski DJ; Choueiri TK; Curran C; Berchuck JE; Harshman LC; Nuzzo PV; Chanza NM; Van Allen E; Esplin ED; Yang S; Callis T; Garber JE; Rana HQ; Sonpavde G
Genet Med; 2020 Apr; 22(4):709-718. PubMed ID: 31844177
[TBL] [Abstract][Full Text] [Related]
31. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C
PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080
[TBL] [Abstract][Full Text] [Related]
32. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
[TBL] [Abstract][Full Text] [Related]
33. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
34. Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
Karppinen SM; Barkardottir RB; Backenhorn K; Sydenham T; Syrjäkoski K; Schleutker J; Ikonen T; Pylkäs K; Rapakko K; Erkko H; Johannesdottir G; Gerdes AM; Thomassen M; Agnarsson BA; Grip M; Kallioniemi A; Kere J; Aaltonen LA; Arason A; Møller P; Kruse TA; Borg A; Winqvist R
J Med Genet; 2006 Nov; 43(11):856-62. PubMed ID: 16825437
[TBL] [Abstract][Full Text] [Related]
35. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
De Brakeleer S; De Grève J; Loris R; Janin N; Lissens W; Sermijn E; Teugels E
Hum Mutat; 2010 Mar; 31(3):E1175-85. PubMed ID: 20077502
[TBL] [Abstract][Full Text] [Related]
36. Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder.
Küry S; Ebstein F; Mollé A; Besnard T; Lee MK; Vignard V; Hery T; Nizon M; Mancini GMS; Giltay JC; Cogné B; McWalter K; Deb W; Mor-Shaked H; Li H; Schnur RE; Wentzensen IM; Denommé-Pichon AS; Fourgeux C; Verheijen FW; Faurie E; Schot R; Stevens CA; Smits DJ; Barr E; Sheffer R; Bernstein JA; Stimach CL; Kovitch E; Shashi V; Schoch K; Smith W; van Jaarsveld RH; Hurst ACE; Smith K; Baugh EH; Bohm SG; Vyhnálková E; Ryba L; Delnatte C; Neira J; Bonneau D; Toutain A; Rosenfeld JA; ; Audebert-Bellanger S; Gilbert-Dussardier B; Odent S; Laumonnier F; Berger SI; Smith ACM; Bourdeaut F; Stern MH; Redon R; Krüger E; Margueron R; Bézieau S; Poschmann J; Isidor B
Am J Hum Genet; 2022 Feb; 109(2):361-372. PubMed ID: 35051358
[TBL] [Abstract][Full Text] [Related]
37. Is there more to BARD1 than BRCA1?
Irminger-Finger I; Jefford CE
Nat Rev Cancer; 2006 May; 6(5):382-91. PubMed ID: 16633366
[TBL] [Abstract][Full Text] [Related]
38. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
39. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
Yurgelun MB; Chittenden AB; Morales-Oyarvide V; Rubinson DA; Dunne RF; Kozak MM; Qian ZR; Welch MW; Brais LK; Da Silva A; Bui JL; Yuan C; Li T; Li W; Masuda A; Gu M; Bullock AJ; Chang DT; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar MD; Wollison BM; Khalaf N; Perez K; Syngal S; Aguirre AJ; Hahn WC; Meyerson ML; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Nowak JA; Wolpin BM
Genet Med; 2019 Jan; 21(1):213-223. PubMed ID: 29961768
[TBL] [Abstract][Full Text] [Related]
40. Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
Zheng Y; Li B; Pan D; Cao J; Zhang J; Wang X; Li X; Hou W; Bao D; Ren L; Yang J; Wang S; Qiu Y; Zhou F; Liu Z; Zhu S; Zhang L; Qing T; Wang Y; Yu Y; Wu J; Hu X; Shi L
Breast Cancer Res; 2021 May; 23(1):53. PubMed ID: 33933153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
